Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.
about
Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids MetabolismGenetics of Common Antipsychotic-Induced Adverse EffectsGenetic Variation in One-Carbon Metabolism and Changes in Metabolic Parameters in First-Episode Schizophrenia Patients.Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general populationDiagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review.Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuseMeta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia.Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.Associations of MTHFR C677T and MTRR A66G gene polymorphisms with metabolic syndrome: a case-control study in Northern China.Relationship between Metabolic Syndrome and MTHFR Polymorphism in Colorectal Cancer.Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs).Whole genome sequencing of an ethnic Pathan (Pakhtun) from the north-west of PakistanThe promise and reality of pharmacogenetics in psychiatryEndothelial function, folate pharmacogenomics, and neurocognition in psychotic disordersThe influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populationsCardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychoticsDNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder.Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.DNA methylation in schizophrenia subjects: gender and MTHFR 677C/T genotype differencesAn Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar DisorderRisk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics.The effect of folate supplementation and genotype on cardiovascular and epigenetic measures in schizophrenia subjects.The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia.Metabolic syndrome in people with schizophrenia: a review.A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controlsNutritional and safety outcomes from an open-label micronutrient intervention for pediatric bipolar spectrum disorders.Metabolic syndrome in schizophrenia.Sex-specific differences in side effects of psychotropic drugs: genes or gender?Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.Pharmacogenetics of response to antipsychotics in patients with schizophrenia.Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia.The multidimensional nature of metabolic syndrome in schizophrenia: lessons from studies of one-carbon metabolism and DNA methylation.Genetics of antipsychotic-induced weight gain: update and current perspectives.Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children.Association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and age of onset in schizophrenia.Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.No association between genetic or epigenetic variation in insulin growth factors and antipsychotic-induced metabolic disturbances in a cross-sectional sample.Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy.Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.
P2860
Q26864342-6B2E7FF0-F788-4EAF-BDD4-7BC19D409450Q28067617-42693732-D644-424E-A0C6-977D22713A72Q28072893-A31520F8-92C9-4AE9-BE9C-0A2961B21D4CQ33614164-39410E66-C2BA-41DB-8EC3-E52E332876CCQ33622056-831D1804-3F39-4C1E-8E53-3BF963B3A131Q33707443-712B6274-D0D9-468E-92BF-855B0038BBC4Q34018212-EBD2AB60-9BEF-46F2-BA2A-B7A4148B3809Q34048609-F97EB654-203A-4E82-A978-C3B8648B8859Q34484974-48A60C1A-6EAF-4DA7-8920-B71671A2B89EQ34833599-98E1F8E5-3DCD-4A7D-BD42-A130DD690749Q34971242-F35E3741-0EBB-4736-9D49-188542C14996Q35116048-8B511B44-B111-4E04-B91F-93EFA5638A40Q35184947-F8805720-6FB3-4F21-ACB1-4B10DCCBFFDDQ35226451-3EEB7238-BC87-4B68-BDD3-6B2CC70C7B48Q35537186-C8C3C4CA-B990-444E-B15A-2CB4C60B001AQ35591977-8553FBE8-6393-44B3-840B-F42788141E44Q35844289-3540E812-01F6-47CA-999F-58CB0308BD25Q35848001-75EA2757-C0C1-45A0-AE03-39B064941FDBQ36063735-78A2616A-99E1-4EC2-A185-9A012904B220Q36084594-59F48772-CAA9-4BB4-A074-B93830F49EE5Q36225284-B7090DAF-30A8-4A6E-ACB0-EC07134AAFCCQ36755212-6E819670-AD1C-427C-88F8-F18659541337Q36848333-10431F34-7E69-4031-BD76-7D58198C422BQ36874705-67A77694-E492-4749-A394-1930FE85B0B3Q37129646-89CAB080-C738-4EB9-9F95-85B70EADCBE5Q37236162-35315F00-0FB0-4548-9900-013A7FBB9B17Q37244943-6B1ACC08-C4BD-41CE-BF6B-F016456A3F57Q37290165-F8F99A2C-B278-4C33-BB40-52940BCD6FA8Q37598900-C25587BA-AF15-4358-B01D-ADE1DEBBFADFQ37926893-E03F2868-FF85-40A9-876E-603DC9C7E8BDQ37952823-B0327566-491B-4EB8-96A9-4919A71755E5Q37960512-2800A1F6-F123-48CA-83EA-180E8A0BB606Q38113237-7ADDB57F-1845-4FC4-81FD-FFE20FE07474Q38166456-F595CEF7-5882-47B9-B93E-5B5188F7A680Q38536898-677B94EF-622E-4DA4-ACED-92782EECF6AEQ43278134-648392B5-90A1-4D2F-8BEA-1D1D4263C012Q43646107-277DEF24-E874-447F-88CC-DA4CC8345CEEQ46195221-9FDC6D7B-754E-49B0-A3B8-EB55CC81DB1AQ47312891-01E92A1D-6FD7-42D1-9830-08C083B87115Q49024766-A2B4A04F-A629-4C83-9515-7935C51811D8
P2860
Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Metabolic syndrome and insulin ...... ) 677C/T and 1298A/C variants.
@ast
Metabolic syndrome and insulin ...... ) 677C/T and 1298A/C variants.
@en
type
label
Metabolic syndrome and insulin ...... ) 677C/T and 1298A/C variants.
@ast
Metabolic syndrome and insulin ...... ) 677C/T and 1298A/C variants.
@en
prefLabel
Metabolic syndrome and insulin ...... ) 677C/T and 1298A/C variants.
@ast
Metabolic syndrome and insulin ...... ) 677C/T and 1298A/C variants.
@en
P2093
P2860
P1476
Metabolic syndrome and insulin ...... ) 677C/T and 1298A/C variants.
@en
P2093
Del D Miller
Jessica Moline
Stephan F Taylor
Timothy Holman
Vicki L Ellingrod
P2860
P356
10.1016/J.SCHRES.2007.09.030
P407
P577
2007-10-31T00:00:00Z